Liminal Biosciences is a clinical-stage biopharmaceutical company focused on discovering, developing and commercializing novel treatments for patients suffering from diseases related to fibrosis. The company is advancing promising research in small molecules for a range of diseases related to fibrosis including respiratory, liver and renal diseases. Through a separate business unit called Prometic, the company also focuses on the use of bioseparation technologies to isolate and purify biopharmaceuticals derived from human plasma.